BNP Paribas Financial Markets Boosts Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

BNP Paribas Financial Markets lifted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 209.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 168,194 shares of the company's stock after purchasing an additional 113,796 shares during the quarter. BNP Paribas Financial Markets owned 0.05% of Amneal Pharmaceuticals worth $1,332,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. Barclays PLC raised its position in shares of Amneal Pharmaceuticals by 134.1% in the 3rd quarter. Barclays PLC now owns 296,384 shares of the company's stock worth $2,466,000 after purchasing an additional 169,756 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Amneal Pharmaceuticals in the 4th quarter worth about $520,000. Amundi purchased a new position in Amneal Pharmaceuticals in the 4th quarter worth about $256,000. Franklin Resources Inc. raised its position in Amneal Pharmaceuticals by 4.9% in the 3rd quarter. Franklin Resources Inc. now owns 89,887 shares of the company's stock worth $778,000 after buying an additional 4,178 shares during the last quarter. Finally, Entropy Technologies LP purchased a new position in Amneal Pharmaceuticals in the 4th quarter worth about $259,000. Hedge funds and other institutional investors own 31.82% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AMRX. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $9.00 to $12.00 in a research report on Monday, February 24th. Barclays boosted their target price on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research report on Monday, March 3rd. Finally, Wall Street Zen lowered Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $11.50.

Amneal Pharmaceuticals Stock Down 0.4%

Shares of Amneal Pharmaceuticals stock traded down $0.03 during trading hours on Friday, reaching $7.16. 1,091,544 shares of the stock traded hands, compared to its average volume of 1,452,224. The company has a 50 day moving average price of $7.62 and a 200 day moving average price of $8.05. The firm has a market capitalization of $2.24 billion, a price-to-earnings ratio of -10.53 and a beta of 1.17. Amneal Pharmaceuticals, Inc. has a one year low of $6.29 and a one year high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its quarterly earnings results on Friday, May 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.05. The business had revenue of $695.42 million during the quarter, compared to the consensus estimate of $714.78 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. Sell-side analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 80,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.90, for a total transaction of $712,000.00. Following the completion of the transaction, the director now directly owns 1,808,886 shares in the company, valued at approximately $16,099,085.40. The trade was a 4.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the business's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $8.35, for a total value of $41,750,000.00. Following the transaction, the insider now owns 48,578,209 shares of the company's stock, valued at approximately $405,628,045.15. This trade represents a 9.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 26.56% of the company's stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.